Diclofenac Sodium (Dicloran)

Diclofenac sodium is a benzene-acetic acid derivative. The chemical name is 2-[(2, 6-dichlorophenyl) amino] benzeneacetic acid, monosodium salt.
Therapeutic class: Non-steroidal anti-inflammatory


Diclofenac is 100% absorbed after oral administration. However, due to first-pass metabolism, only about 50% of the absorbed dose is systematically available. Food has no significant effect on the extent of diclofenac absorption.

Diclofenac sodium is a benzene-acetic acid derivative


Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites

Indications and usage

Relief of signs and symptoms of osteoarthritis
Relief of signs and symptoms of rheumatoid arthritis
Acute or long term use in the relief of signs and symptoms of ankylosing spondylitis


Dicloran is contraindicated in patients with known hypersensitivity to diclofenac. Dicloran should not be given to patients who have experienced asthma, urticarial or other allergic type reactions after taking aspirin or other NSAIDs


Serious gastrointestinal toxicity such as inflammation, bleeding, ulceration and perforation of the stomach, small intestine or large intestine, can occur at any time with or without warning symptoms, in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). Minor upper gastrointestinal problems, such as dyspepsia, are common and may also occur at any time during NSAID therapy. Therefore physicians and patients should remain alert for ulceration and bleeding even in absence of previous GI tract symptoms. Patients should be informed about the signs and/or symptoms of serious GI toxicity and the steps to take if they occur.


There are no adequate and well-controlled studies in pregnant women. Because of the unknown effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy should be avoided

Post a comment